pharmaphorum

AUGUST 7, 2025

Skip to main content Thursday 7 August 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views (..)

Diabetes

pharmaphorum

JUNE 27, 2025

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Drug Development

European Pharmaceutical Review

JANUARY 25, 2024

In a survey conducted by The European Consumer Organisation (BEUC) during June and July 2022, in Belgium, Italy, Portugal and Spain, 79 percent of consumers said paper leaflets should be available inside the package even if there is an alternative QR code on it. 11 This requirement directly contradicts what is included in Article 63.

Packaging

Pharmaceutical Technology

MAY 11, 2008

Pharmaceutical companies, regulatory agencies and governments are becoming increasingly concerned about fraud and counterfeiting throughout the pharmaceutical supply chain, especially with the cost of drugs going up. Europe is favouring 2D data matrix codes to encode information while the US is tending more towards RFID.

Packaging

Pharmaceutical Technology

MARCH 22, 2023

According to the GlobalData report Contract Injectable Packaging Trends in the Bio/Pharma Industry , more than half (55%) of FDA drug approvals in 2021 were accounted for by injectables. During the Covid-19 pandemic, large-scale vaccine production placed unprecedented demand on the parenteral packaging industry.

Packaging

PharmaShots

JUNE 7, 2023

To further expedite the introduction of the biosimilar globally, EirGenix has been in talks with global pharmaceutical companies about licensing the marketing rights to EG1206A 5. The P-III trial of EG1206A is expected to be initiated shortly, estimated that the evaluation of the primary EPs will be completed within 2yrs.

Biosimilars